---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-017046"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:35:27.330116+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kezar sells Sec61 assets (incl. KZR-261) to Enodia for $1M upfront, up to $127M milestones

## Summary
- Kezar receives $1M cash upfront ($800K at close, $200K later) for its Sec61-based discovery program and KZR-261.
- Eligible for up to $127M in development, regulatory and commercial milestone payments plus tiered royalties on net sales.
- Kezar retains its zetomizomib program; no other assets (cash, equipment, employee contracts) transferred.
- Transaction closed March 6, 2026; joint press release issued March 12, 2026.
- Agreement includes indemnification caps of $1M per party (excluding fraud) and customary covenants.

## SEC filing metadata
- accession: 0001628280-26-017046
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000162828026017046/0001628280-26-017046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000162828026017046/kzr-20260306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-017046
- JSON: https://secwatch.observer/filing/0001628280-26-017046.json
- Plain text: https://secwatch.observer/filing/0001628280-26-017046.txt

## Source-grounded claims
- claim_id: b529fb9d85a42aeb9b76b79079bb17abf8f397c0
  claim: Kezar Life Sciences, Inc. completed a disposition involving Enodia Therapeutics SAS for $800,000 in cash at the closing (closed 2026-03-06).
  evidence_excerpt: assets related to the Company’s zetomizomib program, employee contracts, cash, accounts receivable, real property or equipment. Pursuant to the Agreement, the Company received $800,000 in cash at the closing and will receive an additional $200,000 on the earlier to occur of (i) physical delivery of certain inventory assets to Enodia and (ii) 45 days after the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000162828026017046/0001628280-26-017046-index.htm
- claim_id: 2750a3fbf3d25dfb1406d679b09a4fe125b67136
  claim: Kezar Life Sciences, Inc. entered into Asset Purchase Agreement with Enodia Therapeutics SAS valued at $800,000 in cash at the closing and will receive an additional $200,000 on the earlier to occur of ( (effective 2026-03-06).
  evidence_excerpt: On March 6, 2026, Kezar Life Sciences, Inc. (the “Company”) and Enodia Therapeutics SAS, a French simplified joint stock company (“Enodia”), entered into an asset purchase agreement (the “Agreement”) pursuant to which Enodia (i) acquired all of the Company’s rights, title and interest in the Company’s Sec61-based discovery and development program assets, including the product candidate internally known as KZR-261 (collectively, the “Assets”); and (ii) assumed liabilities from the Company related to certain transferred contracts and from the ownership, use, operation or maintenance of the Assets under the Agreement (the “Transaction”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000162828026017046/0001628280-26-017046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.